Molecular markers for bladder cancer: the road to a multimarker approach

Bladder cancer is the seventh most common malignancy worldwide, with almost 14,000 patients dying from this disease in the USA alone. Because of the need for long-term and frequent follow-up, as well as the paucity of sensitive and specific noninvasive tests, bladder cancer management has the highest cost per patient among all cancer types. Several molecular markers, especially members of the cell cycle regulation and apoptosis pathways, have been investigated. However, no individual marker has been prognostically powerful enough to change clinical management. The combined analysis of a panel of markers spanning different pathways is the most promising approach. We give an overview of the most important molecular markers functioning in crucial pathways and focus on their role in multimarker analysis.

[1]  E. Ioachim.  Expression patterns of cyclins D1, E and cyclin‐dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki‐67 and PCNA) and clinicopathological features , 2008, International journal of clinical practice.

[2]  G. Nesi,et al.  Loss of P16 expression and chromosome 9p21 LOH in predicting outcome of patients affected by superficial bladder cancer. , 2007, The Journal of surgical research.

[3]  K. Steven,et al.  Radical cystectomy and extended pelvic lymphadenectomy: survival of patients with lymph node metastasis above the bifurcation of the common iliac vessels treated with surgery only. , 2007, The Journal of urology.

[4]  Torben F. Ørntoft,et al.  Emmprin and Survivin Predict Response and Survival following Cisplatin-Containing Chemotherapy in Patients with Advanced Bladder Cancer , 2007, Clinical Cancer Research.

[5]  R. Montironi,et al.  BCL-2, TP53 and BAX protein expression in superficial urothelial bladder carcinoma. , 2007, Cancer letters.

[6]  N. Socci,et al.  A Polymorphism in HDM2 (SNP309) Associates with Early Onset in Superficial Tumors, TP53 Mutations, and Poor Outcome in Invasive Bladder Cancer , 2007, Clinical Cancer Research.

[7]  M. Duffy,et al.  Survivin: a promising tumor biomarker. , 2007, Cancer letters.

[8]  Y. Lotan,et al.  Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness , 2007, Modern Pathology.

[9]  L. Kiemeney,et al.  Gene expression analysis for the prediction of recurrence in patients with primary Ta urothelial cell carcinoma. , 2007, European urology.

[10]  C. Roehrborn,et al.  Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. , 2007, The Lancet. Oncology.

[11]  Ram H Datar,et al.  Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Y. Lotan,et al.  Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. , 2006, Human pathology.

[13]  T. Frebourg,et al.  Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations. , 2006, The Journal of urology.

[14]  S. Fulda,et al.  Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy , 2006, Oncogene.

[15]  L. Kiemeney,et al.  The Predictive Value of p53, p27Kip1, and α-Catenin for Progression in Superficial Bladder Carcinoma , 2006 .

[16]  F. Boccardo,et al.  Prognostic value of cell cycle regulatory proteins in muscle-infiltrating bladder cancer , 2006, Journal of Cancer Research and Clinical Oncology.

[17]  Kwang Dong Kim,et al.  Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells. , 2006, Cancer letters.

[18]  R. Montironi,et al.  Cyclin D3 expression in primary Ta/T1 bladder cancer , 2006, The Journal of pathology.

[19]  M. Soloway,et al.  The diagnosis and staging of bladder cancer: from RBCs to TURs. , 2006, Urology.

[20]  Carlos Cordon-Cardo,et al.  Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  K. Kawamoto,et al.  p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer. , 2006, Biochemical and biophysical research communications.

[22]  N. Malats,et al.  P53 as a prognostic marker for bladder cancer: a meta-analysis and review. , 2005, The Lancet. Oncology.

[23]  J. Wei,et al.  Survivin protein expression positively correlated with proliferative activity of cancer cells in bladder cancer. , 2005, Indian journal of medical sciences.

[24]  William L. Bigbee,et al.  Multiplexed Immunobead-Based Cytokine Profiling for Early Detection of Ovarian Cancer , 2005, Cancer Epidemiology Biomarkers & Prevention.

[25]  Ming Xu,et al.  Using tree analysis pattern and SELDI-TOF-MS to discriminate transitional cell carcinoma of the bladder cancer from noncancer patients. , 2005, European urology.

[26]  Y. Maehara,et al.  Regulation of p27 by S-phase kinase-associated protein 2 is associated with aggressiveness in non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  R. Montironi,et al.  Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors: the role of G1-S modulators (p53, p21Waf1, p27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters. , 2004, American journal of clinical pathology.

[28]  A. Lopez‐Beltran,et al.  Prognostic Factors in Survival of Patients With Stage Ta and T1 Bladder Urothelial Tumors , 2004 .

[29]  Peter A. Jones,et al.  Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer , 2004, The Journal of pathology.

[30]  E. Ioachim,et al.  Expression Patterns of Cyclins D1, E and Cyclin-Dependent Kinase Inhibitors p21(Waf1/Cip1) and p27(Kip1) in Urothelial Carcinoma: Correlation with Other Cell-Cycle-Related Proteins (Rb, p53, Ki-67 and PCNA) and Clinicopathological Features , 2004, Urologia internationalis.

[31]  G. Capellá,et al.  p53 and p21 expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined‐modality approach , 2004, Cancer.

[32]  R. Montironi,et al.  Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, Cyclin D1, and Cyclin D3) and proliferation index (ki67-MIB1). , 2004, European urology.

[33]  Yupo Ma,et al.  p150Sal2 Is a p53-Independent Regulator of p21WAF1/CIP , 2004, Molecular and Cellular Biology.

[34]  S. Shariat,et al.  p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  S. Groshen,et al.  Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  T. Tzai,et al.  The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer. , 2004, Urologic oncology.

[37]  Fengzhi Li.  Survivin study: What is the next wave? , 2003, Journal of cellular physiology.

[38]  Jose M. Silva,et al.  Prevalence of aberrant methylation of p14ARF over p16INK4a in some human primary tumors. , 2003, Mutation research.

[39]  R. Aebersold,et al.  Mass spectrometry-based proteomics , 2003, Nature.

[40]  S. Hsu,et al.  Involvement of mitochondrial pathway in Taxol-induced apoptosis of human T24 bladder cancer cells , 2002, Urological Research.

[41]  A. Lazaris,et al.  Immunohistochemical study of pro-apoptotic factors Bax, Fas and CPP32 in urinary bladder cancer: prognostic implications , 2002, Urological Research.

[42]  H. Moch,et al.  Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer , 2002, Oncogene.

[43]  P. Korkolopoulou,et al.  Differential expression of bcl-2 family proteins in bladder carcinomas. Relationship with apoptotic rate and survival. , 2002, European urology.

[44]  A. Cittadini,et al.  Cyclin D1 expression in papillary superficial bladder cancer: Its association with other cell cycle‐associated proteins, cell proliferation and clinical outcome , 2002, International journal of cancer.

[45]  S. Pita-Fernández,et al.  p53 and ki67 expression as prognostic factors for cancer-related survival in stage T1 transitional cell bladder carcinoma. , 2002, European urology.

[46]  K. H. Lee,et al.  Proteomics: a technology-driven and technology-limited discovery science. , 2001, Trends in biotechnology.

[47]  M. Marberger,et al.  Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2. , 2001, The Journal of urology.

[48]  A. Hart,et al.  Apoptosis, proliferation and p53, cyclin D1, and retinoblastoma gene expression in relation to radiation response in transitional cell carcinoma of the bladder. , 2001, International journal of radiation oncology, biology, physics.

[49]  T. Ebert,et al.  p53 Immunohistochemistry as a Prognostic Marker in Bladder Cancer , 2000, European Urology.

[50]  W. Schulz,et al.  Cyclin-dependent kinase inhibitor P27(KIP1) is expressed preferentially in early stages of urothelial carcinoma. , 2000, Urology.

[51]  T. Koshikawa,et al.  Immunohistochemical demonstration of cyclin D1 in bladder cancers as an inverse indicator of invasiveness but not an independent prognostic factor , 2000, International journal of urology : official journal of the Japanese Urological Association.

[52]  V. Kosma,et al.  Evaluation of p21WAF1/CIP1 and cyclin D1 expression in the progression of superficial bladder cancer , 2000, Urological Research.

[53]  T Hardmeier,et al.  High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. , 2000, The American journal of pathology.

[54]  A. Cittadini,et al.  Loss of p21Waf1 expression is a strong predictor of reduced survival in primary superficial bladder cancers. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[55]  P. Cooke,et al.  Bcl‐2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy , 2000, BJU international.

[56]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[57]  A. Levine,et al.  P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[58]  P. Lara,et al.  Apoptosis in carcinoma of the bladder: relation with radiation treatment results. , 1999, International journal of radiation oncology, biology, physics.

[59]  P. Keane,et al.  Apoptosis and its clinical significance for bladder cancer therapy , 1999, BJU international.

[60]  Karen H. Vousden,et al.  p14ARF links the tumour suppressors RB and p53 , 1998, Nature.

[61]  S. Groshen,et al.  Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. , 1998, Journal of the National Cancer Institute.

[62]  W. Schulz,et al.  Expression of G1→S Transition Regulatory Molecules in Human Urothelial Cancer , 1998, Japanese journal of cancer research : Gann.

[63]  B. Têtu,et al.  The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index. , 1998, British journal of urology.

[64]  C. Dinney,et al.  p53 and RB expression predict progression in T1 bladder cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[65]  B. Clurman,et al.  The CDKN2A tumor-suppressor locus--a tale of two proteins. , 1998, The New England journal of medicine.

[66]  Yue Xiong,et al.  ARF Promotes MDM2 Degradation and Stabilizes p53: ARF-INK4a Locus Deletion Impairs Both the Rb and p53 Tumor Suppression Pathways , 1998, Cell.

[67]  S. Groshen,et al.  Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. , 1998, Cancer research.

[68]  B. Czerniak,et al.  Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[69]  D. Green,et al.  The Release of Cytochrome c from Mitochondria: A Primary Site for Bcl-2 Regulation of Apoptosis , 1997, Science.

[70]  Peter A. Jones,et al.  p53 and treatment of bladder cancer , 1997, Nature.

[71]  Bert Vogelstein,et al.  Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21 , 1996, Nature.

[72]  James M. Roberts,et al.  Requirement of p27Kip1 for Restriction Point Control of the Fibroblast Cell Cycle , 1996, Science.

[73]  H. Shiina,et al.  Immunohistochemical analysis of bcl-2 expression in transitional cell carcinoma of the bladder. , 1996, Journal of clinical pathology.

[74]  S. Korsmeyer.  Regulators of cell death. , 1995, Trends in genetics : TIG.

[75]  S C Chen,et al.  Accumulation of nuclear p53 and tumor progression in bladder cancer. , 1994, The New England journal of medicine.

[76]  James M. Roberts,et al.  Cloning of p27 Kip1 , a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals , 1994, Cell.

[77]  John Calvin Reed,et al.  Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. , 1994, Oncogene.

[78]  M. Tilby,et al.  Differential sensitivity to the induction of apoptosis by cisplatin in proliferating and quiescent immature rat thymocytes is independent of the levels of drug accumulation and DNA adduct formation. , 1994, Cancer research.

[79]  Thea D. Tlsty,et al.  Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53 , 1992, Cell.

[80]  C. Cordon-Cardo,et al.  Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. , 1992, Journal of the National Cancer Institute.

[81]  A. Sahin,et al.  Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. , 1992, Journal of the National Cancer Institute.

[82]  D. Lane,et al.  p53, guardian of the genome , 1992, Nature.

[83]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[84]  J. Hickman,et al.  Drug-target interactions: only the first step in the commitment to a programmed cell death? , 1991, British Journal of Cancer.

[85]  Joseph R. Nevins,et al.  The E2F transcription factor is a cellular target for the RB protein , 1991, Cell.

[86]  W Lutzeyer,et al.  Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. , 1982, The Journal of urology.

[87]  A. Althausen,et al.  Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. , 1976, The Journal of urology.

[88]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[89]  Yupo Ma,et al.  p150(Sal2) is a p53-independent regulator of p21(WAF1/CIP). , 2004, Molecular and cellular biology.

[90]  D. Altieri.  Validating survivin as a cancer therapeutic target , 2003, Nature Reviews Cancer.

[91]  B. Czerniak,et al.  Apoptosis and downstaging after preoperative radiotherapy for muscle-invasive bladder cancer. , 1996, International journal of radiation oncology, biology, physics.